RESUMEN
Advanced breast cancer remains a significant oncological challenge, requiring new approaches to improve clinical outcomes. This study investigated an innovative theranostic agent using the MCM-41-NH2-DTPA-Gd3âº-MIH nanomaterial, which combined MRI imaging for detection and a novel chemotherapy agent (MIH 2.4Bl) for treatment. The nanomaterial was based on the mesoporous silica type, MCM-41, and was optimized for drug delivery via functionalization with amine groups and conjugation with DTPA and complexation with Gd3+. MRI sensitivity was enhanced by using gadolinium-based contrast agents, which are crucial in identifying early neoplastic lesions. MIH 2.4Bl, with its unique mesoionic structure, allows effective interactions with biomolecules that facilitate its intracellular antitumoral activity. Physicochemical characterization confirmed the nanomaterial synthesis and effective drug incorporation, with 15% of MIH 2.4Bl being adsorbed. Drug release assays indicated that approximately 50% was released within 8 h. MRI phantom studies demonstrated the superior imaging capability of the nanomaterial, with a relaxivity significantly higher than that of the commercial agent Magnevist. In vitro cellular cytotoxicity assays, the effectiveness of the nanomaterial in killing MDA-MB-231 breast cancer cells was demonstrated at an EC50 concentration of 12.6 mg/mL compared to an EC50 concentration of 68.9 mg/mL in normal human mammary epithelial cells (HMECs). In vivo, MRI evaluation in a 4T1 syngeneic mouse model confirmed its efficacy as a contrast agent. This study highlighted the theranostic capabilities of MCM-41-NH2-DTPA-Gd3âº-MIH and its potential to enhance breast cancer management.
Asunto(s)
Neoplasias de la Mama , Imagen por Resonancia Magnética , Nanopartículas , Dióxido de Silicio , Nanomedicina Teranóstica , Dióxido de Silicio/química , Animales , Humanos , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/patología , Femenino , Nanomedicina Teranóstica/métodos , Imagen por Resonancia Magnética/métodos , Ratones , Línea Celular Tumoral , Nanopartículas/química , Antineoplásicos/farmacología , Antineoplásicos/química , Antineoplásicos/uso terapéutico , Medios de Contraste/química , Gadolinio/química , Porosidad , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
BACKGROUND: For cancer patient populations worldwide, the synchronous scale-up of diagnostics and treatments yields meaningful gains in survival and quality of life. Among advanced cancer therapies, radiotherapy (RT) and theranostics are key to achieving practical, high-quality, and personalized precision medicine - targeting disease manifestations of individual patients and broad populations, alike. Aiming to learn from one another across different world regions, the six country vignettes presented here depict both challenges and victories in de novo establishment or improvement of RT and theranostics infrastructure. METHODS: The International Atomic Energy Agency (IAEA) convened global RT and theranostics experts from diverse world regions and contexts to identify relevant challenges and report progress in their own six countries: Belgium, Brazil, Costa Rica, Jordan, Mongolia, and South Africa. These accounts are collated, compared, and contrasted herein. RESULTS: Common challenges persist which could be more strategically assessed and addressed. A quantifiable discrepancy entails personnel. The estimated radiation oncologists (ROs), nuclear medicine physicians (NMPs), and medical physicists (MPs for RT and nuclear medicine) per million inhabitants in the six collective countries respectively range between 2.69-38.00 ROs, 1.00-26.00 NMPs, and 0.30-3.45 MPs (Table 1), reflecting country-to-country inequities which largely match World Bank country-income stratifications. CONCLUSION: Established goals for RT and nuclear medicine advancement worldwide have proven elusive. The pace of progress could be hastened by enhanced approaches such as more sustainably phased implementation; better multinational networking to share lessons learned; routine quality and safety audits; as well as capacity building employing innovative, resource-sparing, cutting-edge technologic approaches. Bodies such as ministries of health, professional societies, and the IAEA shall serve critical roles in convening and coordinating more innovative RT and theranostics translational research, including expanding nuanced global database metrics to inform, reach, and potentiate milestones most meaningfully. POLICY SUMMARY: Aligned with WHO 25×25 NCDs target; WHA70.12 and WHA76.5 resolutions.
Asunto(s)
Neoplasias , Humanos , Neoplasias/radioterapia , Sudáfrica , Jordania , Brasil , Costa Rica , Medicina de Precisión , Radioterapia , Nanomedicina TeranósticaRESUMEN
Nanotechnology has changed the world, with a great impact on industry and medicine. In this commentary, we discuss the importance of radiolabeled nanomaterials for the construction of theranostic, imaging and therapeutic agents in order to pave the future of medicine.
Asunto(s)
Nanoestructuras , Radiofármacos , Radiofármacos/uso terapéutico , Nanoestructuras/uso terapéutico , Nanotecnología , Diagnóstico por Imagen , Nanomedicina TeranósticaRESUMEN
Among the most lethal forms of cancer, malignant brain tumors persist as one of the greatest challenges faced by oncologists, where nanotechnology-driven theranostics can play a critical role in developing novel polymer-based supramolecular nanoarchitectures with multifunctional and multi-modal characteristics to fight cancer. However, it is virtually a consensus that, besides the complexity of active delivering anticancer drugs by the nanocarriers to the tumor site, the current evaluation methods primarily relying on in vitro assays and in vivo animal models have been accounted for the low translational effectiveness to clinical applications. In this view, the chick chorioallantoic membrane (CAM) assay has been increasingly recognized as one of the best preclinical models to study the effects of anticancer drugs on the tumor microenvironment (TME). Thus, in this study, we designed, characterized, and developed novel hybrid nanostructures encompassing chemically functionalized carboxymethylcellulose (CMC) with mitochondria-targeting pro-apoptotic peptide (KLA) and cell-penetrating moiety (cysteine, CYS) with fluorescent inorganic semiconductor (Ag-In-S, AIS) for simultaneously bioimaging and inducing glioblastoma cancer cell (U-87 MG, GBM) death. The results demonstrated that the CMC-peptide macromolecules produced supramolecular vesicle-like nanostructures with aqueous colloidal stability suitable as nanocarriers for passive and active targeting of cancer tumors. The optical properties and physicochemical features of the nanoconjugates confirmed their suitability as photoluminescent nanoprobes for cell bioimaging and intracellular tracking. Moreover, the results in vitro demonstrated a notable killing activity towards GBM cells of cysteine-bearing CMC conjugates coupled with pro-apoptotic KLA peptides. More importantly, compared to doxorubicin (DOX), a model anticancer drug in chemotherapy that is highly toxic, these innovative nanohybrids nanoconjugates displayed higher lethality against U-87 MG cancer cells. In vivo CAM assays validated these findings where the nanohybrids demonstrated a significant reduction of GBM tumor progression (41% area) and evidenced an antiangiogenic activity. These results pave the way for developing polymer-based hybrid nanoarchitectonics applied as targeted multifunctional theranostics for simultaneous imaging and therapy against glioblastoma while possibly reducing the systemic toxicity and side-effects of conventional anticancer chemotherapeutic agents.
Asunto(s)
Antineoplásicos , Neoplasias Encefálicas , Glioblastoma , Puntos Cuánticos , Animales , Antineoplásicos/química , Neoplasias Encefálicas/tratamiento farmacológico , Carboximetilcelulosa de Sodio/química , Línea Celular Tumoral , Cisteína , Doxorrubicina/química , Glioblastoma/tratamiento farmacológico , Nanoconjugados/uso terapéutico , Polímeros/uso terapéutico , Puntos Cuánticos/química , Nanomedicina Teranóstica , Microambiente TumoralRESUMEN
Hearing loss (HL) is a sensory disability that affects 5 % of the world's population. HL predominantly involves damage and death to the cochlear cells. Currently, there is no cure or specific medications for HL. Furthermore, the arrival of therapeutic molecules to the inner ear represents a challenge due to the limited blood supply to the sensory cells and the poor penetration of the blood-cochlear barrier. Superparamagnetic iron oxide nanoparticles (SPIONs) perfectly coordinate with the requirements for controlled drug delivery along with magnetic resonance imaging (MRI) diagnostic and monitoring capabilities. Besides, they are suitable tools to be applied to HL, expecting to be more effective and non-invasive. So far, the published literature only refers to some preclinical studies of SPIONs for HL management. This contribution aims to provide an integrated view of the best options and strategies that can be considered for future research punctually in the field of magnetic nanotechnology applied to HL.
Asunto(s)
Pérdida Auditiva , Nanomedicina Teranóstica , Sistemas de Liberación de Medicamentos , Pérdida Auditiva/diagnóstico , Pérdida Auditiva/tratamiento farmacológico , Humanos , Imagen por Resonancia Magnética/métodosRESUMEN
This study aimed to evaluate the influence of formulation and procedure parameters in obtaining thick and continuous chitosan/PVA/glycerol nanofibres to be applied in skin care. For that, the polymers were characterized by nuclear magnetic resonance, Fourier-transform infrared spectroscopy, and size-exclusion chromatography. After this, 96 chitosan/PVA/glycerol nanofibre scaffolds were prepared by electrospinning method, using factorial designs. The independent variables were crude and pure chitosan, 2 brands of PVA, 2 needle gauges, high and low polymer concentration, high and low glycerol concentration, and final solution with and without ultrafiltration. Morphological analysis was performed by scanning electron microscopy, atomic force microscopy, and confocal microscopy. The best sample (NF67) presented an average thickness of 268.3 nm, uniform distribution, and high yield. It was obtained at a 1:3.5 (crude chitosan: PVA with lower molecular weight, but more hydrolysed) ratio and lower glycerol concentration, suggesting that the degree of hydrolysis of the PVA is more important than its molecular weight for obtaining better quality nanofibres and that the glycerol also makes the electrospinning process difficult. Thus, it was possible to choose parameters that provide scaffolds that could be applied as a matrix extracellular-like material in wound healing.
Asunto(s)
Quitosano/química , Glicerol/química , Nanofibras/química , Nanofibras/ultraestructura , Alcohol Polivinílico/química , Cuidados de la Piel , Fenómenos Químicos , Quitosano/aislamiento & purificación , Microscopía de Fuerza Atómica , Nanotecnología , Medicina Regenerativa , Análisis Espectral , Nanomedicina TeranósticaRESUMEN
We developed a microfluidic synthesis to grow GdF3:Eu theranostic scintillating nanoparticles to simultaneously monitor the X-ray dose delivered to tumors during treatments with X-ray activated photodynamic therapy (X-PDT). The flow reaction was optimized to enhance scintillation emission from the Eu3+ ions. The as-prepared â¼15 nm rhombohedral-shaped nanoparticles self-assembled into â¼100 nm mesoporous flower-like nanostructures, but the rhombohedral units remained intact and the scintillation spectra unaltered. The conjugation of the ScNPs with multilayers of methylene blue (MB) in a core-shell structure (GdF@MB) resulted in enhanced singlet oxygen (1O2) generation under X-ray irradiation, with maximum 1O2 production for nanoparticles with 4 MB layers (GdF@4MB). High 1O2 yield was further evidenced in cytotoxicity assays, demonstrating complete cell death only for the association of ScNPs with MB and X-rays. Because the scintillating Eu3+ emission at 694 nm is within the therapeutic window and was only partially absorbed by the MB molecules, it was explored for getting in vivo dosimetric information. Using porcine skin and fat to simulate the optical and radiological properties of the human tissues, we showed that the scintillation light can be detected for a tissue layer of â¼16 mm, thick enough to be employed in radiotherapy treatments of breast cancers, for instance. Therefore, the GdF3:Eu ScNPs and the GdF@4MB nanoconjugates are strong candidates for treating cancer with X-PDT while monitoring the treatment and the radiation dose delivered, opening new avenues to develop a next-generation modality of real-time in vivo dosimetry.
Asunto(s)
Materiales Biocompatibles/síntesis química , Dispositivos Laboratorio en un Chip , Nanopartículas/química , Fotoquimioterapia , Fármacos Fotosensibilizantes/síntesis química , Nanomedicina Teranóstica , Materiales Biocompatibles/química , Humanos , Rayos Infrarrojos , Ensayo de Materiales , Tamaño de la Partícula , Fármacos Fotosensibilizantes/química , Rayos XRESUMEN
This contribution describes the design and synthesis of multifunctional micelles based on amphiphilic brush block copolymers (BBCPs) for imaging and selective drug delivery of natural anticancer compounds. Well-defined BBCPs were synthesized via one-pot multi-step sequential grafting-through ring-opening metathesis polymerization (ROMP) of norbornene-based macroinitiators. The norbornenes employed contain a poly(ethylene glycol) methyl ether chain, an alkyl bromide chain, and/or a near-infrared (NIR) fluorescent cyanine dye. After block copolymerization, post-polymerization transformations using bromide-azide substitution, followed by the strain-promoted azide-alkyne cycloaddition (SPAAC) allowed for the functionalization of the BBCPs with the piplartine (PPT) moiety, a natural product with well-documented cytotoxicity against cancer cell lines, via an ester linker between the drug and the polymer side chain. The amphiphilic BBCPs self-assembled in aqueous media into nano-sized spherical micelles with neutral surface charges, as confirmed by dynamic light scattering analysis and transmission electron microscopy. During self-assembly, paclitaxel (PTX) could be effectively encapsulated into the hydrophobic core to form stable PTX-loaded micelles with high loading capacities and encapsulation efficiencies. The NIR fluorescent dye-containing micelles exhibited remarkable photophysical properties, excellent colloidal stability under physiological conditions, and a pH-induced disassembly under slightly acidic conditions, allowing for the release of the drug in a controlled manner. The in vitro studies demonstrated that the micelles without the drug (blank micelles) are biocompatible at concentrations of up to 1 mg mL-1 and present a high cellular internalization capacity toward MCF-7 cancer cells. The drug-functionalized micelles showed in vitro cytotoxicity comparable to free PPT and PTX against MCF-7 and PC3 cancer cells, confirming efficient drug release into the tumor environment upon cellular internalization. Furthermore, the drug-functionalized micelles exhibited higher selectivity than the pristine drugs and preferential cellular uptake in human cancer cell lines (MCF-7 and PC3) when compared to the normal breast cell line (MCF10A). This study provides an efficient strategy for the development of versatile polymeric nanosystems for drug delivery and image-guided diagnostics. Notably, the easy functionalization of BBCP side chains via SPAAC opens up the possibility for the preparation of a library of multifunctional systems containing other drugs or functionalities, such as target groups for recognition.
Asunto(s)
Micelas , Nanomedicina Teranóstica , Portadores de Fármacos/química , Sistemas de Liberación de Medicamentos , Humanos , Norbornanos , Polietilenglicoles/química , Polímeros/químicaRESUMEN
After several decades of development in the field of near-infrared (NIR) dyes for photothermal therapy (PTT), indocyanine green (ICG) still remains the only FDA-approved NIR contrast agent. However, upon NIR light irradiation ICG can react with molecular oxygen to form reactive oxygen species and degrade the ICG core, losing the convenient dye properties. In this work, we introduce a new approach for expanding the application of ICG in nanotheranostics, which relies on the confinement of self-organized J-type aggregates in hydrophobic protein domains acting as monomer depots. Upon the fast photobleaching, while the dye is irradiated, this strategy permits the equilibrium-driven monomer replacement after each irradiation cycle that radically increases the systems' effectivity and applicability. Gadolinium-doped casein micelles were designed to prove this novel concept at the same time as endowing the nanosystems with further magnetic resonance imaging (MRI) ability for dual-modal imaging-guided PTT. By teaching a new trick to a very old dog, the clinical prospect of ICG will undoubtedly be boosted laying the foundation for novel therapeutics. It is anticipated that future research could be expanded to other relevant J-aggregates-forming cyanine dyes or nanocrystal formulations of poorly water-soluble photosensitizers.
Asunto(s)
Colorantes , Nanopartículas , Verde de Indocianina , Fototerapia , Nanomedicina TeranósticaRESUMEN
Introduction: Metal organic frameworks (MOFs) are a recent group of nano porous materials with exceptional physical properties, such as large surface areas, high pore volumes, low densities and well-defined pores. This type of material has been used frequently for biomedical and therapeutic applications, such as drug delivery systems and theranostic materials.Areas covered: In this review, the authors searched for patents filed in the last 10 years, found in different databases, related to the therapeutic or biomedical application of MOFs for use in different health fields. The possibility of these new materials becoming new therapeutic possibilities available to the population was emphasized.Expert opinion: The advances in research with MOFs have grown in the last 10 years and with that many possibilities for their applications have emerged in several areas, especially biomedical. The possibility of using these materials in drug delivery systems is the most common form of possibility of use in the health area, mainly due to easy obtaining and high reproducibility, which are seen very positively by the drug development technology sector.
Asunto(s)
Sistemas de Liberación de Medicamentos , Desarrollo de Medicamentos/métodos , Estructuras Metalorgánicas/química , Animales , Humanos , Patentes como Asunto , Porosidad , Reproducibilidad de los Resultados , Tecnología Farmacéutica/métodos , Nanomedicina TeranósticaRESUMEN
INTRODUCTION: Cancer is the second leading cause of death globally and is responsible, where about 1 in 6 deaths in the world. Therefore, there is a need to develop effective antitumor agents that are targeted only to the specific site of the tumor to improve the efficiency of cancer diagnosis and treatment and, consequently, limit the unwanted systemic side effects currently obtained by the use of chemotherapeutic agents. In this context, due to its unique physical and chemical properties of graphene oxide (GO), it has attracted interest in biomedicine for cancer therapy. METHODS: In this study, we report the in vivo application of nanocomposites based on Graphene Oxide (nc-GO) with surface modified with PEG-folic acid, Rhodamine B and Indocyanine Green. In addition to displaying red fluorescence spectra Rhodamine B as the fluorescent label), in vivo experiments were performed using nc-GO to apply Photodynamic Therapy (PDT) and Photothermal Therapy (PTT) in the treatment of Ehrlich tumors in mice using NIR light (808 nm 1.8 W/cm2). RESULTS: This study based on fluorescence images was performed in the tumor in order to obtain the highest concentration of nc-GO in the tumor as a function of time (time after intraperitoneal injection). The time obtained was used for the efficient treatment of the tumor by PDT/PTT. DISCUSSION: The current study shows an example of successful using nc-GO nanocomposites as a theranostic nanomedicine to perform simultaneously in vivo fluorescence diagnostic as well as combined PDT-PTT effects for cancer treatments.
Asunto(s)
Grafito/química , Fotoquimioterapia , Terapia Fototérmica , Nanomedicina Teranóstica , Adsorción , Animales , Benzofuranos/química , Carcinoma de Ehrlich/patología , Carcinoma de Ehrlich/terapia , Humanos , Verde de Indocianina/farmacología , Masculino , Ratones , Nanocompuestos/química , Tamaño de la Partícula , Rodaminas/farmacología , Espectrometría de Fluorescencia , Espectrometría Raman , Electricidad Estática , Carga TumoralRESUMEN
Polymeric nanoparticles encompass micelles and dendrimers. They are used for improving or controlling the action of the loaded therapy or imaging agent, including radionuclides. Some radionuclides possess properties appropriate for simultaneous imaging and therapy of a disease and are therefore called theranostic. The diversity in core materials and surface modification, as well as radiolabeling strategies, offers multiples possibilities for preparing polymeric nanoparticles using radionuclides. The present review describes different strategies in the preparation of such nanoparticles and their applications in nuclear nanomedicine.
Asunto(s)
Dendrímeros/química , Sistemas de Liberación de Medicamentos , Micelas , Radioisótopos/uso terapéutico , Nanomedicina Teranóstica , Animales , Humanos , Nanopartículas/químicaRESUMEN
Colorectal cancer (CRC) is a major cause of cancer death with a high probability of treatment failure. Doxorubicin (DOXO) is an efficient antitumor drug; however, most CRC cells show resistance to its effects. Magnetic nanoparticles (MNPs) are potential cancer management tools that can serve as diagnostic agents and also can optimize and personalize treatments. This work aims to evaluate the aptitude of magnetic nanotheranostics composed of magnetite (Fe3O4) nanoparticles coated with folic acid intended to the sustained release of DOXO. The administration of DOXO by means of these MNPs resulted in the enhancement of cell death respect to the free drug administration. Chromatin compaction and cytoplasmic protrusions were observed. Mitochondrial transmembrane potential disruption and increased PARP protein cleavage confirmed apoptosis. The nanosystem was also tested as a vectoring tool by exposing it to the stimuli of a static magnetic field in vitro. CRC-related magnetic nanotechnology still remains in pre-clinical trials. In this context, this contribution expands the knowledge of the behavior of MNPs in contact with in vitro models and proposes the nanodevices studied here as potential theranostic agents for the monitoring of the progress of CRC and the evolution of its treatment.
Asunto(s)
Neoplasias Colorrectales , Nanopartículas de Magnetita , Muerte Celular , Línea Celular Tumoral , Neoplasias Colorrectales/tratamiento farmacológico , Doxorrubicina , Humanos , Fenómenos Magnéticos , Nanomedicina TeranósticaRESUMEN
En la era de la medicina personalizada y de precisión, enfocada en mejorar la atención en salud aprovechando al máximo las oportunidades que ofrecen los desarrollos biomédicos, tecnológicos, sociales y económicos de la actualidad, han aparecido nuevos términos como el de teranóstico. Este término nace de la fusión de los conceptos de terapia y diagnóstico y, aunque fue propuesto en años recientes, hace referencia a un abordaje que se ha utilizado desde hace mucho tiempo (1). El teranóstico consiste en una metodología donde el abordaje diagnóstico se hace enfocado hacia la intervención terapéutica individualizada, buscando proporcionar los mejores desenlaces para el paciente. El área de la medicina nuclear ha sido pionera en el teranóstico, pues el primer tratamiento basado en este concepto se realizó con yodo radiactivo (131I) en pacientes con patología tiroidea. Actualmente, con los avances en imagen molecular e imágenes con genes reporteros (2), cada vez se encuentran disponibles más agentes teranósticos para proporcionar terapias individualizadas o "lesionalizadas", como se han empezado a llamar más recientemente (3). En la presente revisión se expone el abordaje teranóstico en medicina nuclear, enfatizando en el funcionamiento, las aplicaciones más frecuentes y la experiencia que se tiene en Colombia.
In the era of personalized and precision medicine, focused on improving health care by making the most of the opportunities offered by current biomedical, technological, social and economic developments, new terms such as theranostic have appeared. This term was born from the fusion of the concepts of therapy and diagnosis and, although it was proposed in recent years, it refers to an approach that has been used for a long time (1). Theranostic consists of a methodology where the diagnostic approach is focused on individualized therapeutic intervention, seeking to provide the best outcomes for the patient. The area of nuclear medicine has been a pioneer in theranostic, since the first treatment based on this concept was performed with radioactive iodine (131I) in patients with thyroid disease. Currently, with advances in molecular imaging and reporter gene imaging (2), more and more theranostic agents are available to provide individualized or "lesionalized" therapies, as they more recently have come to be called (3). In this review, the theranostic approach in nuclear medicine is exposed, emphasizing how it works, what are the most frequent applications and what experience we have in Colombia
Asunto(s)
Nanomedicina Teranóstica , Cintigrafía , Tomografía Computarizada por Tomografía de Emisión de Positrones , Medicina NuclearRESUMEN
Crotoxin (CTX), the main neurotoxin from Crotalus durissus terrificus snake venom, has anti-inflammatory, immunomodulatory and antinociceptive activities. However, the CTX-induced toxicity may compromise its use. Under this scenario, the use of nanoparticle such as nanostructured mesoporous silica (SBA-15) as a carrier might become a feasible approach to improve CTX safety. Here, we determined the benefits of SBA-15 on CTX-related neuroinflammatory and immunomodulatory properties during experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis that replicates several histopathological and immunological features observed in humans. We showed that a single administration of CTX:SBA-15 (54 µg/kg) was more effective in reducing pain and ameliorated the clinical score (motor impairment) in EAE animals compared to the CTX-treated EAE group; therefore, improving the disease outcome. Of interest, CTX:SBA-15, but not unconjugated CTX, prevented EAE-induced atrophy and loss of muscle function. Further supporting an immune mechanism, CTX:SBA-15 treatment reduced both recruitment and proliferation of peripheral Th17 cells as well as diminished IL-17 expression and glial cells activation in the spinal cord in EAE animals when compared with CTX-treated EAE group. Finally, CTX:SBA-15, but not unconjugated CTX, prevented the EAE-induced cell infiltration in the CNS. These results provide evidence that SBA-15 maximizes the immunomodulatory and anti-inflammatory effects of CTX in an EAE model; therefore, suggesting that SBA-15 has the potential to improve CTX effectiveness in the treatment of MS.
Asunto(s)
Crotoxina/administración & dosificación , Encefalomielitis Autoinmune Experimental/etiología , Encefalomielitis Autoinmune Experimental/metabolismo , Inmunomodulación/efectos de los fármacos , Dióxido de Silicio , Nanomedicina Teranóstica , Animales , Biomarcadores , Biopsia , Crotoxina/efectos adversos , Crotoxina/química , Citocinas/metabolismo , Manejo de la Enfermedad , Modelos Animales de Enfermedad , Susceptibilidad a Enfermedades , Encefalomielitis Autoinmune Experimental/diagnóstico , Femenino , Ratones , Músculo Esquelético/inmunología , Músculo Esquelético/metabolismo , Músculo Esquelético/patología , Índice de Severidad de la Enfermedad , Médula Espinal/inmunología , Médula Espinal/metabolismo , Médula Espinal/patología , Evaluación de SíntomasRESUMEN
Gold (AuNP) and silver (AgNP) nanoparticles have been incorporated into many therapeutic and diagnostic applications. However, previous studies revealed toxic properties as well as the hormesis phenomenon of many nanoparticles in different biological models. To evaluate the effects of low concentrations of AuNP and AgNP on murine melanoma cells B16F1 and B16F10 and relate them with phenotype changes, cells were exposed for 24 and 48 h. No cytotoxicity was observed for B16 cells through neutral red, MTT, trypan blue, and crystal violet assays at concentrations from 0.01 to 10 ng mL-1. Likewise, the nanoparticles did not interfere with drug-efflux activity, cell migration, cell cycle, and colony formation. Slight toxicity was observed for B16F10 exposed to 100 ng mL-1, with a decreased number of viable and attached cells, indicating differential sensitivity of B16F1 and B16F10 cells to the nanoparticles. Furthermore, colony size dispersion decreased for both B16 cell sub-lines. Therefore, there is no evidence that the tested concentrations of AuNP and AgNP can render B16 cells more aggressive and malignant, which is important since both nanoparticles are already largely used in nanotechnological products. Considering studies that have showed the hormesis effect of nanoparticles at low concentrations, which could protect cancer cells against chemotherapy, further investigation is advised.
Asunto(s)
Oro/toxicidad , Melanoma Experimental/patología , Nanopartículas del Metal/toxicidad , Plata/toxicidad , Nanomedicina Teranóstica , Animales , Adhesión Celular/efectos de los fármacos , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Hormesis , Ratones , Medición de Riesgo , Factores de TiempoRESUMEN
Despite the undeniable advances in recent decades, cancer remains one of the deadliest diseases of the current millennium, where the triple-negative breast cancer (TNBC) is very aggressive, extremely metastatic, and resistant to conventional chemotherapy. The nanotheranostic approach focusing on targeting membrane receptors often expressed at abnormal levels by cancer cells can be a strategic weapon for fighting malignant tumors. Herein, we introduced a novel "all-in-one nanosoldier" made of colloidal hybrid nanostructures, which were designed for simultaneously targeting, imaging, and killing TNBC cells. These nanohybrids comprised four distinct components: (a) superparamagnetic iron oxide nanoparticles, as bi-functional nanomaterials for inducing ferroptosis via inorganic nanozyme-mediated catalysis and magnetotherapy by hyperthermia treatment; (b) carboxymethyl cellulose biopolymer, as a water-soluble capping macromolecule; (c) folic acid, as the membranotopic vector for targeting folate receptors; (d) and doxorubicin (DOX) drug for chemotherapy. The results demonstrated that this novel strategy was highly effective for targeting and killing TNBC cells in vitro, expressing high levels of folate membrane-receptors. The results evidenced that three integrated mechanisms triggered the deaths of the cancer cells in vitro: (a) ferroptosis, by magnetite nanoparticles inducing a Fenton-like reaction; (b) magneto-hyperthermia effect by generating heat under an alternate magnetic field; and (c) chemotherapy, through the DOX intracellular release causing DNA dysfunction. This "all-in-one nanosoldier" strategy offers a vast realm of prospective alternatives for attacking cancer cells, combining multimodal therapy and the delivery of therapeutic agents to diseased sites and preserving healthy cells, which is one of the most critical clinical challenges faced in fighting drug-resistant breast cancers.
Asunto(s)
Antineoplásicos/química , Doxorrubicina/química , Colorantes Fluorescentes/química , Nanopartículas de Magnetita/química , Nanocápsulas/química , Neoplasias de la Mama Triple Negativas/diagnóstico por imagen , Neoplasias de la Mama Triple Negativas/terapia , Antineoplásicos/uso terapéutico , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Permeabilidad de la Membrana Celular , Terapia Combinada , Doxorrubicina/farmacología , Doxorrubicina/uso terapéutico , Liberación de Fármacos , Receptores de Folato Anclados a GPI/metabolismo , Ácido Fólico/química , Ácido Fólico/metabolismo , Humanos , Hipertermia Inducida/efectos adversos , Campos Magnéticos , Nanopartículas de Magnetita/uso terapéutico , Terapia Molecular Dirigida , Imagen Óptica , Estudios Prospectivos , Especies Reactivas de Oxígeno/metabolismo , Nanomedicina TeranósticaRESUMEN
The cancer multidrug resistance is involved in the failure of several treatments during cancer treatment. It is a phenomenon that has been receiving great attention in the last years due to the sheer amount of mechanisms discovered and involved in the process of resistance which hinders the effectiveness of many anti-cancer drugs. Among the mechanisms involved in the multidrug resistance, the participation of ATP-binding cassette (ABC) transporters is the main one. The ABC transporters are a group of plasma membrane and intracellular organelle proteins involved in the process of externalization of substrates from cells, which are expressed in cancer. They are involved in the clearance of intracellular metabolites as ions, hormones, lipids and other small molecules from the cell, affecting directly and indirectly drug absorption, distribution, metabolism and excretion. Other mechanisms responsible for resistance are the signaling pathways and the anti- and pro-apoptotic proteins involved in cell death by apoptosis. In this study we evaluated the influence of three nanosystem (Graphene Quantum Dots (GQDs), mesoporous silica (MSN) and poly-lactic nanoparticles (PLA)) in the main mechanism related to the cancer multidrug resistance such as the Multidrug Resistance Protein-1 and P-glycoprotein. We also evaluated this influence in a group of proteins involved in the apoptosis-related resistance including cIAP-1, XIAP, Bcl-2, BAK and Survivin proteins. Last, colonogenic and MTT (3-(4,5-dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) assays have also been performed. The results showed, regardless of the concentration used, GQDs, MSN and PLA were not cytotoxic to MDA-MB-231 cells and showed no impairment in the colony formation capacity. In addition, it has been observed that P-gp membrane expression was not significantly altered by any of the three nanomaterials. The results suggest that GQDs nanoparticles would be suitable for the delivery of other multidrug resistance protein 1 (MRP1) substrate drugs that bind to the transporter at the same binding pocket, while MSN can strongly inhibit doxorubicin efflux by MRP1. On the other hand, PLA showed moderate inhibition of doxorubicin efflux by MRP1 suggesting that this nanomaterial can also be useful to treat MDR (Multidrug resistance) due to MRP1 overexpression.
Asunto(s)
Transportadoras de Casetes de Unión a ATP/genética , Transportadoras de Casetes de Unión a ATP/metabolismo , Resistencia a Múltiples Medicamentos , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/genética , Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antineoplásicos/administración & dosificación , Apoptosis/efectos de los fármacos , Línea Celular Tumoral , Técnica del Anticuerpo Fluorescente , Expresión Génica , Grafito/química , Humanos , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/genética , Proteínas Asociadas a Resistencia a Múltiples Medicamentos/metabolismo , Nanopartículas/química , Nanoestructuras/química , Nanomedicina TeranósticaRESUMEN
Delivery efficiencies of theranostic nanoparticles (NPs) based on passive tumor targeting strongly depend either on their blood circulation time or on appropriate modulations of the tumor microenvironment. Therefore, predicting the NP delivery efficiency before and after a tumor microenvironment modulation is highly desirable. Here, we present a new erythrocyte membrane-camouflaged magnetofluorescent nanocarrier (MMFn) with long blood circulation time (92 h) and high delivery efficiency (10% ID for Ehrlich murine tumor model). MMFns owe their magnetic and fluorescent properties to the incorporation of manganese ferrite nanoparticles (MnFe2O4 NPs) and IR-780 (a lipophilic indocyanine fluorescent dye), respectively, to their erythrocyte membrane-derived camouflage. MMFn composition, morphology, and size, as well as optical absorption, zeta potential, and fluorescent, magnetic, and magnetothermal properties, are thoroughly examined in vitro. We then present an analytical pharmacokinetic (PK) model capable of predicting the delivery efficiency (DE) and the time of peak tumor uptake (tmax), as well as changes in DE and tmax due to modulations of the tumor microenvironment, for potentially any nanocarrier. Experimental PK data sets (blood and tumor amounts of MMFns) are simultaneously fit to the model equations using the PK modeling software Monolix. We then validate our model analytical solutions with the numerical solutions provided by Monolix. We also demonstrate how our a priori nonmechanistic model for passive targeting relates to a previously reported mechanistic model for active targeting. All in vivo PK studies, as well as in vivo and ex vivo biodistribution studies, were conducted using two noninvasive techniques, namely, fluorescence molecular tomography (FMT) and alternating current biosusceptometry (ACB). Finally, histopathology corroborates our PK and biodistribution results.